{
    "clinical_study": {
        "@rank": "18133", 
        "acronym": "MOP Plus", 
        "arm_group": [
            {
                "arm_group_label": "sublingual buprenorphine", 
                "arm_group_type": "Experimental", 
                "description": "Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose"
            }, 
            {
                "arm_group_label": "oral morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after\n      utero exposure to opioids. Sublingual buprenorphine shows promise as a new treatment in NAS.\n       This trial will investigate the safety and tolerability of sublingual buprenorphine in\n      infants exposed to both opioids and benzodiazepines in utero or with exposure of opioids in\n      those who are breastfeeding."
        }, 
        "brief_title": "Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neonatal Abstinence Syndrome", 
        "condition_browse": {
            "mesh_term": "Neonatal Abstinence Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Infants with in utero exposure to opioids often require therapy with morphine for an\n      extended period. In a clinical trial, sublingual buprenorphine reduced this treatment period\n      by ~30%.  However, infants with both opioid and benzodiazepine exposure were not included in\n      the trial.  This study will test the safety and tolerability of sublingual buprenorphine in\n      infants with in utero exposure to benzodiazepines or who are breastfeeding."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u2265 37 weeks gestation\n\n          2. Exposure to opioids in utero\n\n          3. Demonstration of signs and symptoms of neonatal abstinence syndrome requiring\n             treatment\n\n          4. Exposure to benzodiazepines in utero and/or receiving breast milk.  Benzodiazepine\n             use is defined as maternal use in the past 30 days, and/or receipt of benzodiazepines\n             by prescription (as determined by self-report or intake urine) by the mother 30 days\n             prior to birth.\n\n        Exclusion Criteria:\n\n          1. Major congenital malformations and/or intrauterine growth retardation defined as\n             birth weight <2200 gm\n\n          2. Medical illness requiring intensification of medical therapy.  This includes, but is\n             not limited to suspected sepsis requiring antibiotic therapy.\n\n          3. Hypoglycemia requiring treatment with intravenous dextrose\n\n          4. Bilirubin >20 mg/dL (The need for phototherapy is not exclusionary)\n\n          5. Seizure activity or other neurologic abnormality"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671410", 
            "org_study_id": "12D.398"
        }, 
        "intervention": [
            {
                "arm_group_label": "oral morphine", 
                "intervention_name": "oral morphine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sublingual buprenorphine", 
                "intervention_name": "sublingual buprenorphine", 
                "intervention_type": "Drug", 
                "other_name": "buprenex"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neonatal Abstinence Syndrome", 
            "buprenorphine", 
            "morphine", 
            "benzodiazepine"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Thomas Jefferson University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Walter K Kraft, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Susan Adeniyi-Jones, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Karol Kaltenbach, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jay Greenspan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Heather L Aldridge, CRNP, NNP-BC", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michelle Epstein, CRNP", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eileen Skiffington, PNP", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label Clinical Trial of Buprenorphine in the Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding", 
        "other_outcome": [
            {
                "description": "To compare the feeding patterns, weight gain, and incidence of feeding dysfunction in infants treated with sublingual buprenorphine and oral morphine for NAS", 
                "measure": "Feeding patterns", 
                "safety_issue": "No", 
                "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }, 
            {
                "description": "To compare the respiratory patterns of infants receiving sublingual buprenorphine or morphine solution for the pharmacologic treatment of NAS after in utero exposure to opioids and benzodiazepines and/or postnatal breast milk.", 
                "measure": "Respiratory Patterns", 
                "safety_issue": "Yes", 
                "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }
        ], 
        "overall_contact": {
            "email": "walter.kraft@jefferson.edu", 
            "last_name": "Walter K Kraft, MD", 
            "phone": "215 955 9077"
        }, 
        "overall_contact_backup": {
            "email": "sadeniyi@nemours.org", 
            "last_name": "Susan Adeniyi-Jones, MD", 
            "phone": "215 955 2893"
        }, 
        "overall_official": {
            "affiliation": "Thomas Jefferson University", 
            "last_name": "Walter K Kraft, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution.", 
            "measure": "Length of treatment", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This endpoint will compare length of stay (in days) using sublingual buprenorphine or oral morphine", 
                "measure": "Length of hospitalization", 
                "safety_issue": "No", 
                "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }, 
            {
                "description": "This endpoint will compare requirement number of patients who require use of supplemental phenobarbital for treatment of NAS", 
                "measure": "Number of patients requiring supplemental phenobarbital treatment", 
                "safety_issue": "No", 
                "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }, 
            {
                "description": "Adverse events will be collected, graded by severity, and assessed for causality referent to study drug.", 
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }
        ], 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}